Through the Palace Walls: Blood-Brain Barrier Transport Technologies
This article was originally published in Start Up
Executive Summary
Delivering compounds across the blood-brain barrier remains the rate limiting step in brain-drug development, yet the problem generally gets ignored until it's too late. Several biotechs are bringing novel strategies to finding a solution, focusing especially on brain cancers. Success may open the floodgates of CNS drug development.
You may also be interested in...
In ArmaGen, Investors Seek A Brain-Penetrating Breakthrough
For years, traditional VCs passed on ArmaGen’s technology that pulls drugs across the blood-brain barrier to reach previously undruggable targets. But in 2012, a syndicate of corporate investors obliged, suggesting they don’t mind losing their money if they can learn more about a difficult problem.
With Geron Deal Done, AngioChem Turns To Its Own Pipeline
A $35 million agreement gets Geron a cancer drug that can cross the blood brain barrier - and gives AngioChem financial runway for its own pursuits.
With Geron Deal Done, AngioChem Turns To Its Own Pipeline
A $35 million agreement gets Geron a cancer drug that can cross the blood brain barrier - and gives AngioChem financial runway for its own pursuits.